Difference between revisions of "Veltuzumab (hA20)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead")
m (Text replacement - ".com/doi/abs" to ".com/doi/full")
Line 2: Line 2:
  
 
==General information==
 
==General information==
−
Class/mechanism: Humanized monoclonal anti-CD20 antibody, which binds to cells expressing CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35).  Veltuzumab has been observed to have apoptotic, anti-proliferative, and antibody-dependent cellular cytotoxic (ADCC) effects.<ref>[http://www.immunomedics.com/veltuzumab.shtml Veltuzumab (hA20) manufacturer's website]</ref><ref>Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009 Jan 29;113(5):1062-70. Epub 2008 Oct 21. [http://bloodjournal.hematologylibrary.org/content/113/5/1062.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18941114 PubMed]</ref><ref>Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009 Jul 10;27(20):3346-53. Epub 2009 May 18. [http://jco.ascopubs.org/content/27/20/3346.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19451441 PubMed]</ref><ref>Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010 May;51(5):747-55. [http://informahealthcare.com/doi/abs/10.3109/10428191003672123 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20214444 PubMed]</ref><ref>Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, Goldenberg DM. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica. 2011 Apr;96(4):567-73. Epub 2010 Dec 20. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069234/ link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21173095 PubMed]</ref>
+
Class/mechanism: Humanized monoclonal anti-CD20 antibody, which binds to cells expressing CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35).  Veltuzumab has been observed to have apoptotic, anti-proliferative, and antibody-dependent cellular cytotoxic (ADCC) effects.<ref>[http://www.immunomedics.com/veltuzumab.shtml Veltuzumab (hA20) manufacturer's website]</ref><ref>Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009 Jan 29;113(5):1062-70. Epub 2008 Oct 21. [http://bloodjournal.hematologylibrary.org/content/113/5/1062.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18941114 PubMed]</ref><ref>Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009 Jul 10;27(20):3346-53. Epub 2009 May 18. [http://jco.ascopubs.org/content/27/20/3346.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19451441 PubMed]</ref><ref>Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010 May;51(5):747-55. [http://informahealthcare.com/doi/full/10.3109/10428191003672123 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20214444 PubMed]</ref><ref>Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, Goldenberg DM. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica. 2011 Apr;96(4):567-73. Epub 2010 Dec 20. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069234/ link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21173095 PubMed]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: no information
 
<br>Extravasation: no information

Revision as of 19:38, 23 February 2018

In clinical trials. Also known as IMMU-160.

General information

Class/mechanism: Humanized monoclonal anti-CD20 antibody, which binds to cells expressing CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35). Veltuzumab has been observed to have apoptotic, anti-proliferative, and antibody-dependent cellular cytotoxic (ADCC) effects.[1][2][3][4][5]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Clinical trials

Patient drug information

No information available.

References

  1. ↑ Veltuzumab (hA20) manufacturer's website
  2. ↑ Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009 Jan 29;113(5):1062-70. Epub 2008 Oct 21. link to original article PubMed
  3. ↑ Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009 Jul 10;27(20):3346-53. Epub 2009 May 18. link to original article PubMed
  4. ↑ Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010 May;51(5):747-55. link to original article PubMed
  5. ↑ Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, Goldenberg DM. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica. 2011 Apr;96(4):567-73. Epub 2010 Dec 20. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Veltuzumab_(hA20)&oldid=24352"